IMAKREBIN

Main information

  • Trade name:
  • IMAKREBIN Film-coated tablet 100MG
  • Dosage:
  • 100MG
  • Pharmaceutical form:
  • Film-coated tablet
  • Administration route:
  • Oral use
  • Units in package:
  • 20 Blister
  • Prescription type:
  • on prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • IMAKREBIN Film-coated tablet 100MG
    Czech Republic
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Imatinib
  • Product summary:
  • TBL FLM 20X100MG

Other information

Status

  • Source:
  • SUKL - Státní ústav pro kontrolu léčiv
  • Authorization status:
  • R - active MA/authorised medicinal product
  • Authorization number:
  • 44/ 134/13-C
  • Last update:
  • 23-11-2016

27-6-2018

Glivec (Novartis Europharm Limited)

Glivec (Novartis Europharm Limited)

Glivec (Active substance: Imatinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4087 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/406/T/110

Europe -DG Health and Food Safety

11-6-2018

Pradaxa (Boehringer Ingelheim International GmbH)

Pradaxa (Boehringer Ingelheim International GmbH)

Pradaxa (Active substance: dabigatran etexilate mesilate) - Centralised - 2-Monthly update - Commission Decision (2018)3755 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/829/II/108

Europe -DG Health and Food Safety

15-5-2018

Imatinib Teva B.V. (Teva B.V.)

Imatinib Teva B.V. (Teva B.V.)

Imatinib Teva B.V. (Active substance: imatinib) - Centralised - Withdrawal - Commission Decision (2018)3008 of Tue, 15 May 2018

Europe -DG Health and Food Safety